GlaxoSmithKline (GSK) has announced Health Canada approval of a BRAF-inhibitor, Tafinlar, and a first in class MEK-inhibitor, Mekinist, for melanoma patients with BRAF V600 mutation. Both, Tafinlar (dabrafenib mesylate) and Mekinist ...
Tags: Melanoma Drugs, Medicine